In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporterss

Drug Metabolism and Disposition

Volumn 41, Issue 3, 2013, Pages 668-681

  Chu, Xiaoyan ^a   Cai, Xiaoxin ^a   Cui, Donghui ^a   Tang, Cuyue ^a   Ghosal, Anima ^a   Chan, Grace ^a   Green, Mitchell D ^a   Kuo, Yuhsin ^a   Liang, Yuexia ^a   MacIolek, Cheri M ^a   Palamanda, Jairam ^a   Evers, Raymond ^a   Prueksaritanont, Thomayant ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATORVASTATIN; BOCEPREVIR; BREAST CANCER RESISTANCE PROTEIN; COTRANSPORTER; CYCLOSPORIN A; CYTOCHROME P450 3A; ESTRONE SULFATE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; KETOCONAZOLE; LOPINAVIR; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; ORGANIC ANION TRANSPORTING POLYPEPTIDE 2B1; ORGANIC CATION TRANSPORTER; PIPERAZINE ESTRONE SULFATE; PITAVASTATIN; RIFAMPICIN; RITONAVIR; ROSUVASTATIN; SODIUM TAUROCHOLATE COTRANSPORTING PEPTIDE; TELAPREVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; MALE; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; TRANSCYTOSIS;

ANIMALS; ANTIVIRAL AGENTS; BIOTRANSFORMATION; CHO CELLS; CRICETINAE; CRICETULUS; CYTOCHROME P-450 CYP3A; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; ENZYMES; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; LIVER; LLC-PK1 CELLS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MICROSOMES, LIVER; ORGANIC ANION TRANSPORTERS; OXIDOREDUCTASES; PROLINE; RECOMBINANT PROTEINS; SWINE; TRANSFECTION;

EID: 84874104694     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049668     Document Type: Article

References (58)

1. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, and Boparai N, et al.; HCV RESPOND-2 Investigators (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207-1217.
2. Busti AJ, Bain AM, Hall RG, 2nd, Bedimo RG, Leff RD, Meek C, and Mehvar R (2008) Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 51:605-610.
3. Chen SH and Tan SL (2005) Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr Med Chem 12:2317-2342.
4. Chu XY, Huskey SE, Braun MP, Sarkadi B, Evans DC, and Evers R (2004) Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. Pharmacol Exp Ther 309 J. 156-164
5. Deng S, Chen XP, Cao D, Yin T, Dai ZY, Luo J, Tang L, and Li YJ (2009) Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. Clin Ther 31:1256-1263.
6. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, and Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drugdrug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
7. Foote BS, Spooner LM, and Belliveau PP (2011) Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother 45:1085-1093.
8. Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, and van Heeswijk RP (2012) Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 52: 1566-1573.
9. Ghosal A, Yuan Y, Tong W, Su AD, Gu C, Chowdhury SK, Kishnani NS, and Alton KB (2011) Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 39:510-521.
10. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
11. Griffin L, Annaert P, and Brouwer KL (2011) Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci 100:3636-3654.
12. Gui C, Obaidat A, Chaguturu R, and Hagenbuch B (2010) Development of a cell-based highthroughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 4:1-8.
13. He YJ, Zhang W, Chen Y, Guo D, Tu JH, Xu LY, Tan ZR, Chen BL, Li Z, and Zhou G, et al. (2009) Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T.C polymorphism. Clin Chim Acta 405:49-52.
14. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236.
15. Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, and Prueksaritanont T (2004) Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 21:1686-1691.
16. Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, Youngberg SP, Wagner JA, and Butterton JR (2012a) Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis DOI: [published ahead of print]
17. Hulskotte EG, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, and Butterton J (2012b) Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 56:1622-1630.
18. Hulskotte EG, Gupta S, Xuan F, van Zutven MG, O'Mara E, Galitz L, Wagner JA, and Butterton JR (2011) Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor boceprevir and the HMG-CoA reductase inhibitors atorvastatin and pravastatin, in 16th Annual Meeting of HEP DART; 2001 December 4-8
19. Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, Hirota T, Irie S, Shimizu H, and Noguchi T, et al. (2011) Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics 21:495-505.
20. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, and Sugiyama Y (2006) Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34: 1109-1115.
21. Jiménez-Nácher I, Alvarez E, Morello J, Rodriguez-Nóvoa S, de Andrés S, and Soriano V (2011) Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol 7:457-477.
22. Jumes P, Feng H-P, Xuan F, Youngberg S, Wagner J, and Butterton J (2012) Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and digoxin in healthy adult volunteers, in 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, 2012 June 27-28, Cambridge, MA
23. Karlgren M, Ahlin G, Bergström CA, Svensson R, Palm J, and Artursson P (2012) In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res 29:411-426.
24. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
25. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drugdrug interactions. Pharmacol Ther 106:97-132.
26. Kilford PJ, Gertz M, Houston JB, and Galetin A (2008) Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos 36:1194-1197.
27. Kiser JJ, Burton JR, Anderson PL, and Everson GT (2012) Review and management of drug interactions with boceprevir and telaprevir. Hepatology 55:1620-1628.
28. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, and Hoody DW (2008) Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 47:570-578.
29. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, and Ravendhran N, et al.; SPRINT-1 investigators (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705-716.
30. Lau YY, Huang Y, Frassetto L, and Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194-204.
31. Lau YY, Okochi H, Huang Y, and Benet LZ (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771.
32. Lee JE, van Heeswijk R, Alves K, Smith F, and Garg V (2011) Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 55:4569-4574.
33. Lin JH (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23:1089-1116.
34. Madan A, Usuki E, Burton L, Ogilvie B, and Parkinson A (2002) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug metabolizing enzymes responsible for the metabolism of drugs, in Drug-Drug Interactions (Rodrigues AD, ed), pp 217-294, Marcel Dekker, New York
35. Maddur H and Kwo PY (2011) Boceprevir. Hepatology 54:2254-2257.
36. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, and Sugiyama Y (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575-581.
37. Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, and Hesk D, et al. (2006) SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 50:1013-1020.
38. Monteagudo E, Fonsi M, Chu X, Bleasby K, Evers R, Pucci V, Orsale MV, Cianetti S, Ferrara M, and Harper S, et al. (2010) The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease. Xenobiotica 40:826-839.
39. Müller F and Fromm MF (2011) Transporter-mediated drug-drug interactions. Pharmacogenomics 12:1017-1037.
40. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
41. Noé J, Portmann R, Brun ME, and Funk C (2007) Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308-1314.
42. Obach RS (2009) Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 12:81-89.
43. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
44. Oswald S, Nassif A, Modess C, Keiser M, Ulrich A, Runge D, Hanke U, Lütjohann D, Engel A, and Weitschies W, et al. (2011) Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther 89:524-528.
45. Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, and Ogilvie BW (2011) An evaluation of the dilution method for identifying metabolismdependent inhibitors of cytochrome P450 enzymes. Drug Metab Dispos 39:1370-1387.
46. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, and Boparai N, et al. SPRINT-2 Investigators (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195-1206.
47. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, and Baillie TA (2002) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512.
48. Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, and Gibson C, et al. (2011) Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 89:234-242.
49. Shitara Y (2011) Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet 26:220-227.
50. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
51. Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K, and Yamada H (2006) Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34: 1277-1282.
52. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
53. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, and Partovi N (2012) A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 11:179-185.
54. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
55. Xia CQ, Milton MN, and Gan LS (2007) Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 8:341-363.
56. Yamada A, Maeda K, Ishiguro N, Tsuda Y, Igarashi T, Ebner T, Roth W, Ikushiro S, and Sugiyama Y (2011) The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics 21:523-530.
57. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, and Humphreys WG (2005) In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729-1739.
58. Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322.